FI117374B - Hyperglykemian vastaisesti vaikuttavat lääkeaineet - Google Patents

Hyperglykemian vastaisesti vaikuttavat lääkeaineet Download PDF

Info

Publication number
FI117374B
FI117374B FI953256A FI953256A FI117374B FI 117374 B FI117374 B FI 117374B FI 953256 A FI953256 A FI 953256A FI 953256 A FI953256 A FI 953256A FI 117374 B FI117374 B FI 117374B
Authority
FI
Finland
Prior art keywords
moxonidine
parts
treatment
patients
amino
Prior art date
Application number
FI953256A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953256A (fi
FI953256A0 (fi
Inventor
Elbert Kaan
Dieter Ziegler
Reinhard Brueckner
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of FI953256A0 publication Critical patent/FI953256A0/fi
Publication of FI953256A publication Critical patent/FI953256A/fi
Application granted granted Critical
Publication of FI117374B publication Critical patent/FI117374B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
FI953256A 1994-07-01 1995-06-30 Hyperglykemian vastaisesti vaikuttavat lääkeaineet FI117374B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel
DE4423177 1994-07-01

Publications (3)

Publication Number Publication Date
FI953256A0 FI953256A0 (fi) 1995-06-30
FI953256A FI953256A (fi) 1996-01-02
FI117374B true FI117374B (fi) 2006-09-29

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953256A FI117374B (fi) 1994-07-01 1995-06-30 Hyperglykemian vastaisesti vaikuttavat lääkeaineet

Country Status (23)

Country Link
US (1) US5712283A (sk)
EP (1) EP0689837B1 (sk)
JP (1) JP3841846B2 (sk)
KR (1) KR100366130B1 (sk)
CN (1) CN1092961C (sk)
AT (1) ATE210444T1 (sk)
AU (1) AU691580B2 (sk)
CA (1) CA2152998C (sk)
CZ (1) CZ287563B6 (sk)
DE (2) DE4423177A1 (sk)
DK (1) DK0689837T3 (sk)
DZ (1) DZ1894A1 (sk)
ES (1) ES2167385T3 (sk)
FI (1) FI117374B (sk)
HU (1) HU226946B1 (sk)
IL (1) IL113411A (sk)
NO (1) NO307029B1 (sk)
NZ (1) NZ270990A (sk)
PT (1) PT689837E (sk)
RU (1) RU2145857C1 (sk)
SK (1) SK282227B6 (sk)
UA (1) UA27954C2 (sk)
ZA (1) ZA954691B (sk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
PL330637A1 (en) * 1996-06-06 1999-05-24 Lilly Co Eli Agent for and method of treating hypostatic cardiac insufficiency
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
BRPI0415198A (pt) * 2003-10-10 2006-12-05 Solvay Pharm Gmbh composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
AU691580B2 (en) 1998-05-21
DK0689837T3 (da) 2002-03-11
FI953256A (fi) 1996-01-02
KR100366130B1 (ko) 2003-03-26
SK74995A3 (en) 1996-05-08
HUT72599A (en) 1996-05-28
UA27954C2 (uk) 2000-10-16
DE4423177A1 (de) 1996-01-04
EP0689837A3 (de) 1996-06-05
IL113411A0 (en) 1995-07-31
KR960003729A (ko) 1996-02-23
HU9501900D0 (en) 1995-08-28
JPH0840906A (ja) 1996-02-13
PT689837E (pt) 2002-04-29
NO952624L (no) 1996-01-02
NO307029B1 (no) 2000-01-31
RU2145857C1 (ru) 2000-02-27
ATE210444T1 (de) 2001-12-15
NO952624D0 (no) 1995-06-30
JP3841846B2 (ja) 2006-11-08
FI953256A0 (fi) 1995-06-30
CN1092961C (zh) 2002-10-23
CZ287563B6 (en) 2000-12-13
CA2152998C (en) 2002-09-03
DE59509928D1 (de) 2002-01-24
CZ139395A3 (en) 1996-01-17
US5712283A (en) 1998-01-27
SK282227B6 (sk) 2001-12-03
AU1775795A (en) 1996-01-18
IL113411A (en) 1999-07-14
ES2167385T3 (es) 2002-05-16
ZA954691B (en) 1996-01-29
HU226946B1 (en) 2010-03-29
EP0689837B1 (de) 2001-12-12
NZ270990A (en) 1997-06-24
CA2152998A1 (en) 1996-01-02
CN1122224A (zh) 1996-05-15
EP0689837A2 (de) 1996-01-03
DZ1894A1 (fr) 2002-02-17

Similar Documents

Publication Publication Date Title
US4708868A (en) Oral anti-diabetic pharmaceutical forms and the preparation thereof
KR100298807B1 (ko) 파킨슨씨병및파킨슨증후군의치료를위한,리루졸을포함하는제약학적조성물
JP2588686B2 (ja) 高脂血症及び動脈硬化症の予防・治療薬
FI117374B (fi) Hyperglykemian vastaisesti vaikuttavat lääkeaineet
EP0812589B1 (en) Combined antipyretic analgesic drug
EP2147671A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
CN111329841B (zh) 格列齐特缓释片及其制备方法
KR20080028415A (ko) ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
KR100709528B1 (ko) 혈당콘트롤용 의약조성물
US6069147A (en) Thermogenesis stimulating drugs
EP1243261B1 (en) Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
IE66378B1 (en) Solid oral forms of application containing ifosfamide as active substance
US5972948A (en) Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US5030630A (en) Use of 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine- for treating diseases caused by reduced secretion of growth hormone
JP2000264839A (ja) 結腸領域で高まった疼痛感応性と関連する機能障害及び／又は下行腸管の疾患の治療及び／又は予防のための医薬調剤並びにその製造法
JP2688266B2 (ja) アルドース還元酵素阻害作用を有し且つ吸収性の良好な薬剤組成物
FI93694B (fi) Aldoosireduktaasien toimintaa estävän farmaseuttisen koostumuksen valmistusmenetelmä
KR102051804B1 (ko) 시롤리무스를 포함하는 우수한 함량균일성을 갖는 약제학적 제제
EP0465091B1 (en) Use of 3-oxygermylpropionic acid to treat cold syndrome
KR20210130663A (ko) 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법
CN100560075C (zh) 调节脂类代谢的药物
CN114557992A (zh) 一种复方药物组合物在制备治疗间质性肺炎药物中的应用
KR20200113116A (ko) 데페라시록스를 포함하는 필름코팅정제
JPS6360926A (ja) 感冒薬
ITFI20010054A1 (it) Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: SOLVAY PHARMACEUTICALS GMBH

FG Patent granted

Ref document number: 117374

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: ABBOTT PRODUCTS GMBH

PC Transfer of assignment of patent

Owner name: ABBOTT LABORATORIES GMBH

MM Patent lapsed